Short answer
Arcus Biosciences, Inc. (RCUS) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 8.01 (Other Events). $269.7 million net proceeds strengthen Arcus’s cash position for development and corporate activities.
Arcus Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $269.7 million net proceeds strengthen Arcus’s cash position for development and corporate activities
- 16,428,572 shares issued at $17.50 public offering price, creating material equity dilution
- Underwriters exercised the full 2,142,857-share option, signaling completed demand for the offering
- Company received $16.45 per share after underwriting discounts and commissions before offering expenses
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcus Biosciences, Inc. 8-K filings
Get the next RCUS 8-K as it lands
Follow RCUS for push alerts, or ask the research agent what this filing means.